Peroxisome Proliferator-activated Receptor-γ (PPARγ) Agonist Improves Coronary Artery Endothelial Function in Diabetic Patients with Coronary Artery Disease

被引：22

作者：

Yu, J. ^{[1
]}

Zhang, Z. ^{[2
]}

Li, Z. ^{[1
]}

Feng, X. ^{[1
]}

He, L. ^{[1
]}

Liu, S. ^{[1
]}

Mao, J. ^{[1
]}

Wang, G. ^{[1
]}

Wang, X. ^{[1
,3
,4
]}

机构：

[1] Peking Univ, Hosp 3, Dept Cardiovasc Med, Beijing 100191, Peoples R China

[2] Peking Univ, Hosp 3, Dept Cardiosurg Med, Beijing 100191, Peoples R China

[3] Peking Univ, Hlth Sci Ctr, Minist Educ, Dept Physiol, Beijing 100191, Peoples R China

[4] Peking Univ, Hlth Sci Ctr, Minist Educ, Key Lab Mol Cardiovasc Sci, Beijing 100191, Peoples R China

来源：

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH | 2010年 / 38卷 / 01期

关键词：

CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENDOTHELIAL FUNCTION; ROSIGLITAZONE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-gamma (PPAR gamma) AGONIST; CORONARY FLOW VELOCITY RESERVE; SMOOTH-MUSCLE-CELLS; NONDIABETIC PATIENTS; INFLAMMATORY MARKERS; DENSITY-LIPOPROTEIN; INSULIN-RESISTANCE; METABOLIC SYNDROME; PIOGLITAZONE; ATHEROSCLEROSIS; ROSIGLITAZONE; EXPRESSION;

D O I：

10.1177/147323001003800110

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The aim of this study was to assess the effect of rosiglitazone on endothelial function of the coronary arteries and on plasma levels of inflammatory markers in diabetic patients with coronary artery disease (CAD). Fifty-six patients with type 2 diabetes and CAD were randomized to receive either rosiglitazone (4 mg/day) or a control for 12 weeks. The coronary flow velocity reserve (CFVR) was assessed using transthoracic Doppler echocardiography at baseline and after 12 weeks. After 12 weeks of rosiglitazone treatment, plasma levels of C-reactive protein were significantly decreased and the median CFVR was significantly increased compared with baseline levels and compared with the control group. These results suggest that, in addition to its beneficial metabolic effects, rosiglitazone, via its anti-inflammatory effects, may improve endothelial function of the coronary arteries in patients with diabetes and CAD.

引用

页码：86 / 94

页数：9

共 25 条

[1] PPARγ activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes [J].

Bagi, Z ;

Koller, A ;

Kaley, G .

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2004, 286 (02) :H742-H748

[2] Peroxisome proliferator-activated receptor γ ligands increase release of nitric oxide from endothelial cells [J].

Calnek, DS ;

Mazzella, L ;

Roser, S ;

Roman, J ;

Hart, CM .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (01) :52-57

[3] Peroxisome proliferator-activated receptor-γ activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors [J].

Campia, U ;

Matuskey, LA ;

Panza, JA .

CIRCULATION, 2006, 113 (06) :867-875

[4]

Hadi HAR, 2007, VASC HEALTH RISK MAN, V3, P853

[5] Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus [J].

Haffner, SM ;

Greenberg, AS ;

Weston, WM ;

Chen, HZ ;

Williams, K ;

Freed, MI .

CIRCULATION, 2002, 106 (06) :679-684

[6]

*INT DIAB FED CLIN, GLOB GUID TYP 2 DIAB

[7] PPAR-γ agonists inhibit production of monocyte inflammatory cytokines [J].

Jiang, CY ;

Ting, AT ;

Seed, B .

NATURE, 1998, 391 (6662) :82-86

[8] Expression and function of PPARγ in rat and human vascular smooth muscle cells [J].

Law, RE ;

Goetze, S ;

Xi, XP ;

Jackson, S ;

Kawano, Y ;

Demer, L ;

Fishbein, MC ;

Meehan, WP ;

Hsueh, WA .

CIRCULATION, 2000, 101 (11) :1311-1318

[9] Pioglitazone, a PPARγ agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats [J].

Majithiya, JB ;

Paramar, AN ;

Balaraman, R .

CARDIOVASCULAR RESEARCH, 2005, 66 (01) :150-161

[10] Metabolic and additional vascular effects of thiazolidinediones [J].

Martens, FMAC ;

Visseren, FLJ ;

Lemay, J ;

de Koning, EJP ;

Rabelink, TJ .

DRUGS, 2002, 62 (10) :1463-1480

← 1 2 3 →